$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Retroviruses insert their genomic DNA into the host genome at various sites. This unique property, which may contribute to the development of cancers and other forms of viral pathogenesis, has the ironic benefit of making these viruses highly amenable to cellular engineering for gene therapy and basic biology research. The viral Integration Site (IS) – the location on the host genome where a foreign DNA (virus) is integrated – has important implications for the fate of both the integrated viruses and the host cells. IS assays have been used in various biological and clinical research settings to study retroviral integration site selection and pathogenesis, cancer development, stem cell biology, and developmental biology1,2,3,4. Low detection sensitivity, poor data reproducibility, and frequent cross-contamination are among the key factors limiting the applications of IS assays to current and planned studies.
Many IS analysis technologies have been developed. Restriction enzyme-based integration site assays, including Linker-Mediated (LM) Polymerase Chain Reaction (PCR)5, inverse PCR6, and Linear-Amplification-Mediated (LAM) PCR7, are the most widely used. The use of site-specific restriction enzymes, however, generates a bias during the retrieval of the IS, allowing only a subset of integromes (a foreign DNA integrated into the host genome) in the vicinity of the restriction site to be recovered4. Assay technologies that more comprehensively assess vector IS have also been introduced in recent years. These assays employ various strategies, including Mu transposon-mediated PCR8, nonrestrictive (nr)-LAM PCR9, type-II restriction enzyme-mediated digestion10, mechanical shearing11, and random hexamer-based PCR (Re-free PCR)12, to fragment genomic DNAs and amplify IS. Current technologies have varying levels of detection sensitivity, genome coverage, target specificity, high-throughput capacity, complexity of assay procedures, and biases in detecting the relative frequencies of target sites. Given the varying qualities of the existing assays and the variety of purposes for which they can be used, the optimal assay approach should be carefully selected.
This work provides detailed experimental procedures and a computational data analysis workflow for a bidirectional assay that significantly improves detection rates and sequence quantification accuracy by simultaneously analyzing the IS upstream and downstream of the integrated target DNA (see Figure 1 for a schematic view of the assay procedures). This approach also provides the means to characterize the retroviral integration process (for example, the fidelity of target site duplication and variations in the genomic sequences of upstream and downstream insertions). Other bidirectional methods have been used primarily for cloning and sequencing both ends of the target DNA11,13,14. This assay is extensively optimized for the high-throughput and reproducible quantification of vector-marked clones, using the well-established LM-PCR method and computational analysis mapping, and for quantifying both upstream and downstream junctions. Bidirectional analysis with the TaqαI enzyme has proven useful for high-throughput clonal quantification in stem cell gene therapy preclinical studies2,15. This paper describes a modified method using a more frequent cutter (RsaI/CviQI - motif: GTAC) that doubles the chances of detecting integromes compared to a TaqαI-based assay. Detailed experimental and data analysis procedures that use GTAC motif enzymes for lentiviral (NL4.3 and its derivatives) and gamma-retroviral (pMX vectors) vector IS analysis are described. The oligonucleotides used in the assay are listed in Table 1. An in-house programming script for IS sequence analysis is provided in the supplemental document.